Bilateral Inflammatory Breast Cancer That Developed Two Years after Treatment for Triple-negative Breast Cancer

被引：0

作者：

Kawaguchi, Yuta ^{[1
,2
]}

Kuba, Sayaka ^{[2
]}

Morita, Michi ^{[2
]}

Meng, Xiangyue ^{[2
]}

Hayashi, Hiroko ^{[3
]}

Kobayashi, Kazuma ^{[2
]}

Adachi, Tomohiko ^{[2
]}

Hidaka, Masaaki ^{[2
]}

Itoh, Shinichiro ^{[2
]}

Kanetaka, Kengo ^{[2
]}

Eguchi, Susumu ^{[2
]}

机构：

[1] Yamaguchi Prefectural Grand Med Ctr, Dept Surg, Hofu, Japan

[2] Nagasaki Univ, Grad Sch Biomed Sci, Dept Surg, Nagasaki, Japan

[3] Nagasaki Univ, Grad Sch Biomed Sci, Dept Pathol, Nagasaki, Japan

来源：

INTERNAL MEDICINE | 2022年 / 61卷 / 15期

关键词：

  bilateral inflammatory breast cancer; dose -dense chemotherapy; triple -negative breast cancer; SURVIVAL; DOXORUBICIN; CONSENSUS; PROGRAM; CELLS;

D O I：

10.2169/internalmedicine.7786-21

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

A 66-year-old woman underwent partial mastectomy and a sentinel lymph node biopsy for left breast can-cer; the pathological diagnosis was invasive ductal carcinoma (pT1aN0, pStage I, triple-negative subtype). Postoperative radiotherapy was performed. Two years later, she developed redness and induration at both breasts. The diagnosis was bilateral inflammatory breast cancer. After four cycles of dose-dense epirubicin and cyclophosphamide followed by 12 weekly paclitaxel cycles, bilateral total mastectomy and axillary lymph node dissection were performed. At the one-year follow-up after undergoing operation and radiother-apy, she remained alive without recurrence. Dose-dense treatment regimens may help patients achieve com-plete resection without short-term recurrence.

引用

页码：2387 / 2391

页数：5

共 21 条

[1] Unusual problems in breast cancer and a rare lung cancer case - Case 3. Simultaneous and synchronous bilateral inflammatory breast cancer [J].

Agrawal, BL ;

Nath, AR ;

Glynn, TP ;

Velazco, D ;

Garnett, RF .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (11) :2218-2220

[2] PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy [J].

Bertucci, Francois ;

Finetti, Pascal ;

Colpaert, Cecile ;

Mamessier, Emilie ;

Parizel, Maxime ;

Dirix, Luc ;

Viens, Patrice ;

Birnbaum, Daniel ;

van Laere, Steven .

ONCOTARGET, 2015, 6 (15) :13506-13519

[3] Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37298 women with early breast cancer in 26 randomised trials [J].

Boddington, C. ;

Bradley, R. ;

Braybrooke, J. ;

Burrett, J. ;

Clarke, M. ;

Davies, C. ;

Davies, L. ;

Dodwell, D. ;

Duane, F. ;

Evans, V. ;

Gettins, L. ;

Godwin, J. ;

Gray, R. ;

Hills, R. ;

James, S. ;

Liu, H. ;

Liu, Z. ;

MacKinnon, E. ;

Mannu, G. ;

McGale, P. ;

McHugh, T. ;

Morris, P. ;

Pan, H. ;

Peto, R. ;

Read, S. ;

Taylor, C. ;

Wang, Y. ;

Wang, Z. ;

Bradley, R. ;

Braybrooke, J. ;

Gray, R. ;

Bergh, J. ;

Peto, R. ;

Gray, Richard ;

Bradley, Rosie ;

Braybrooke, Jeremy ;

Liu, Zulian ;

Peto, Richard ;

Davies, Lucy ;

Dodwell, David ;

McGale, Paul ;

Pan, Hongchao ;

Taylor, Carolyn ;

Barlow, William ;

Bliss, Judith ;

Bruzzi, Paolo ;

Cameron, David ;

Fountzilas, George ;

Loibl, Sibylle ;

Mackey, John .

LANCET, 2019, 393 (10179) :1440-1452

[4] Aldehyde Dehydrogenase 1-Positive Cancer Stem Cells Mediate Metastasis and Poor Clinical Outcome in Inflammatory Breast Cancer [J].

Charafe-Jauffret, Emmanuelle ;

Ginestier, Christophe ;

Iovino, Flora ;

Tarpin, Carole ;

Diebel, Mark ;

Esterni, Benjamin ;

Houvenaeghel, Gilles ;

Extra, Jean-Marc ;

Bertucci, Francois ;

Jacquemier, Jocelyne ;

Xerri, Luc ;

Dontu, Gabriela ;

Stassi, Giorgio ;

Xiao, Yi ;

Barsky, Sanford H. ;

Birnbaum, Daniel ;

Viens, Patrice ;

Wicha, Max S. .

CLINICAL CANCER RESEARCH, 2010, 16 (01) :45-55

[5] International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment [J].

Dawood, S. ;

Merajver, S. D. ;

Viens, P. ;

Vermeulen, P. B. ;

Swain, S. M. ;

Buchholz, T. A. ;

Dirix, L. Y. ;

Levine, P. H. ;

Lucci, A. ;

Krishnamurthy, S. ;

Robertson, F. M. ;

Woodward, W. A. ;

Yang, W. T. ;

Ueno, N. T. ;

Cristofanilli, M. .

ANNALS OF ONCOLOGY, 2011, 22 (03) :515-523

[6]

Ditsch N, 2012, ANTICANCER RES, V32, P3539

[7] Inflammatory breast cancer (IBC): clues for targeted therapies [J].

Fernandez, Sandra V. ;

Robertson, Fredika M. ;

Pei, Jianming ;

Aburto-Chumpitaz, Lucy ;

Mu, Zhaomei ;

Chu, Khoi ;

Alpaugh, R. K. ;

Huang, Yong ;

Cao, Yu ;

Ye, Zaiming ;

Cai, Kathy Q. ;

Boley, Kimberly M. ;

Klein-Szanto, Andres J. ;

Devarajan, Karthik ;

Addya, Sankar ;

Cristofanilli, Massimo .

BREAST CANCER RESEARCH AND TREATMENT, 2013, 140 (01) :23-33

[8] Trends in inflammatory breast carcinoma incidence and survival: The Surveillance, Epidemiology, and End Results Program at the National Cancer Institute [J].

Hance, KW ;

Anderson, WF ;

Devesa, SS ;

Young, HA ;

Levine, PH .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (13) :966-975

[9]

Hashmi Salman, 2012, Cancers (Basel), V4, P156, DOI 10.3390/cancers4010156

[10] Bilateral breast cancer: analysis of incidence, outcome, survival and disease characteristics [J].

Kheirelseid, Elrasheid A. H. ;

Jumustafa, Hanzali ;

Miller, Nicola ;

Curran, Catherine ;

Sweeney, Karl ;

Malone, Carmel ;

McLaughlin, Ray ;

Newell, John ;

Kerin, Michael J. .

BREAST CANCER RESEARCH AND TREATMENT, 2011, 126 (01) :131-140

← 1 2 3 →